|
Wednesday, December 11, 2024, 7:15 PM – 9:15 PM CT (8:15 PM – 10:15 PM ET) | San Antonio, Texas
Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast CancerPart 2 of a 3-Part CME Satellite Symposium Series in Partnership with the 2024 San Antonio Breast Cancer Symposium®
Location
San Antonio Marriott Rivercenter 101 Bowie St San Antonio, Texas Hotel Phone: (210) 223-1000 Program Schedule — Central Time 7:15 PM – 9:15 PM — Educational Dinner Meeting Registration and buffet will open at 7:00 PM CT. Meeting Room Grand Ballroom G-M (Third Floor) This event will also be webcast live. Please see Registration tab for details. Faculty
Matthew P Goetz, MD Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD Professor of Oncology and Pharmacology Enterprise Deputy Director, Translational Research Mayo Clinic Comprehensive Cancer Center Director, Mayo Clinic Breast Cancer SPORE Mayo Clinic Rochester, Minnesota Sara A Hurvitz, MD, FACP Professor Senior Vice President Clinical Research Division Fred Hutchinson Cancer Center Head, Division of Hematology/Oncology UW Medicine Seattle, Washington Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell College of Medicine New York, New York Virginia Kaklamani, MD, DSc Professor of Medicine Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment AB Alexander Distinguished Chair in Oncology Leader, Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center San Antonio, Texas Seth Wander, MD, PhD Assistant Professor of Medicine Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Lilly, Novartis, and Stemline Therapeutics Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Program Schedule — Central Time 7:15 PM – 9:15 PM — Educational Dinner Meeting Registration and buffet will open at 7:00 PM CT. MODULE 1: Role of CDK4/6 Inhibitors in Hormone Receptor (HR)-Positive Localized Breast Cancer
MODULE 2: Incorporation of CDK4/6 Inhibitors into the Management of HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC)
MODULE 3: Evolving Role of PI3K Inhibitors for HR-Positive mBC Harboring PIK3CA Mutations
MODULE 4: Clinical Utility of AKT Inhibitors for Patients with Progressive HR-Positive mBC
MODULE 5: Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive mBC
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr Goetz — Advisory Committees (to Institution): Biotheranostics Inc, Biotheryx, Blueprint Medicines, EcoR1 Capital LLC, Genentech, a member of the Roche Group, Laekna Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Puma Biotechnology Inc; Consulting Agreements (to Institution): ARC Therapeutics, Lilly, Novartis, Seagen Inc, Stemline Therapeutics Inc; Contracted Research (to Institution, PI): AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sermonix Pharmaceuticals; Data and Safety Monitoring Boards/Steering Committees (to Institution): AstraZeneca Pharmaceuticals LP, AstraZeneca UK; Intellectual Property: SimBioSys, VeriSIM Life; Speakers Bureau (CME Activities): Curio Science; Travel Support: Lilly; Nonrelevant Financial Relationships: AXIS Medical Education Inc, BroadcastMed, eChinaHealth, Engage Health Media, IDEOlogy Health, MJH Life Sciences, Physician Education Resource (PER), Total Health Conferencing. Dr Hurvitz — Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, GSK, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc. Dr Jhaveri — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Debiopharm, Eisai Inc, Genentech, a member of the Roche Group,Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. Dr Kaklamani — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, Puma Biotechnology Inc, TerSera Therapeutics LLC; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Sanofi; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc. Dr Wander — Advisory Committees: Biovica International AB, Genentech, a member of the Roche Group, Hologic Inc, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foundation Medicine, Lilly, Novartis; Contracted Research: Genentech, a member of the Roche Group, Lilly, Nuvation Bio, Pfizer Inc, Regor Therapeutics Group, Sermonix Pharmaceuticals; Data and Safety Monitoring Board/Committee: Regor Therapeutics Group; Speakers Bureaus: Guardant Health, Lilly; Nonrelevant Financial Relationship: 2nd.MD. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Lilly, Novartis, and Stemline Therapeutics Inc. San Antonio Marriott Rivercenter
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2024 San Antonio Breast Cancer Symposium®. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |